Patents by Inventor Michael Bibby

Michael Bibby has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods of treating cancer using compounds containing a vascular disrupting agent
    Patent number: 10912839
    Abstract: The present invention relates to prodrugs of vascular disrupting agents comprising a vascular disrupting agent (VDA) associated with a MMP proteolytic cleavage site and to the use of such prodrugs in the targeted treatment of cancer.
    Type: Grant
    Filed: March 1, 2018
    Date of Patent: February 9, 2021
    Assignee: ELLIPSES PHARMA LIMITED
    Inventors: Robert Falconer, Jason Gill, Jennifer Xavier, Paul Loadman, Michael Bibby, Laurence Patterson
  • METHODS OF TREATING CANCER USING COMPOUNDS CONTAINING A VASCULAR DISRUPTING AGENT
    Publication number: 20200316212
    Abstract: The present invention relates to prodrugs of vascular disrupting agents comprising a vascular disrupting agent (VDA) associated with a MMP proteolytic cleavage site and to the use of such prodrugs in the targeted treatment of cancer.
    Type: Application
    Filed: June 19, 2020
    Publication date: October 8, 2020
    Inventors: Robert Andrew Falconer, Jason Gill, Jennifer Xavier, Paul Loadman, Michael Bibby, Laurence Patterson
  • Compounds containing a vascular disrupting agent
    Patent number: 10556014
    Abstract: The present invention relates to compounds, and pharmaceutically acceptable salts thereof, comprising a vascular disrupting agent (VDA) associated and a MMP proteolytic cleavage site. The compounds are useful in the treatment of cancer.
    Type: Grant
    Filed: March 16, 2018
    Date of Patent: February 11, 2020
    Assignee: ELLIPSES PHARMA LIMITED
    Inventors: Jason Gill, Paul Loadman, Rob Falconer, Laurence Patterson, Jennifer Xavier, Michael Bibby
  • COMPOUNDS CONTAINING A VASCULAR DISRUPTING AGENT
    Publication number: 20180228910
    Abstract: The present invention relates to compounds, and pharmaceutically acceptable salts thereof, comprising a vascular disrupting agent (VDA) associated and a MMP proteolytic cleavage site. The compounds are useful in the treatment of cancer.
    Type: Application
    Filed: March 16, 2018
    Publication date: August 16, 2018
    Inventors: Jason Gill, Paul Loadman, Rob Falconer, Laurence Patterson, Jennifer Xavier, Michael Bibby
  • Methods Of Treating Cancer Using Compounds Containing A Vascular Disrupting Agent
    Publication number: 20180177886
    Abstract: The present invention relates to prodrugs of vascular disrupting agents comprising a vascular disrupting agent (VDA) associated with a MMP proteolytic cleavage site and to the use of such prodrugs in the targeted treatment of cancer.
    Type: Application
    Filed: March 1, 2018
    Publication date: June 28, 2018
    Inventors: Robert Falconer, Jason Gill, Jennifer Xavier, Paul Loadman, Michael Bibby, Laurence Patterson
  • Compounds containing a vascular disrupting agent
    Patent number: 9956296
    Abstract: The present invention relates to compounds, and pharmaceutically acceptable salts thereof, comprising a vascular disrupting agent (VDA) associated and a MMP proteolytic cleavage site. The compounds are useful in the treatment of cancer.
    Type: Grant
    Filed: May 6, 2016
    Date of Patent: May 1, 2018
    Assignee: INCANTHERA LTD
    Inventors: Jason Gill, Paul Loadman, Rob Falconer, Laurence Patterson, Jennifer Xavier, Michael Bibby
  • Methods of treating cancer using compounds containing a vascular disrupting agent
    Patent number: 9937267
    Abstract: The present invention relates to prodrugs of vascular disrupting agents comprising a vascular disrupting agent (VDA) associated with a MMP proteolytic cleavage site and to the use of such prodrugs in the targeted treatment of cancer.
    Type: Grant
    Filed: October 19, 2016
    Date of Patent: April 10, 2018
    Assignee: Incanthera Ltd
    Inventors: Robert Andrew Falconer, Jason Gill, Jennifer Xavier, Paul Loadman, Michael Bibby, Laurence Patterson
  • Methods Of Treating Cancer Using Compounds Containing A Vascular Disrupting Agent
    Publication number: 20170266307
    Abstract: The present invention relates to prodrugs of vascular disrupting agents comprising a vascular disrupting agent (VDA) associated with a MMP proteolytic cleavage site and to the use of such prodrugs in the targeted treatment of cancer.
    Type: Application
    Filed: October 19, 2016
    Publication date: September 21, 2017
    Inventors: Robert Andrew Falconer, Jason Gill, Jennifer Xavier, Paul Loadman, Michael Bibby, Laurence Patterson
  • COMPOUNDS CONTAINING A VASCULAR DISRUPTING AGENT
    Publication number: 20160243252
    Abstract: The present invention relates to compounds, and pharmaceutically acceptable salts thereof, comprising a vascular disrupting agent (VDA) associated and a MMP proteolytic cleavage site. The compounds are useful in the treatment of cancer.
    Type: Application
    Filed: May 6, 2016
    Publication date: August 25, 2016
    Inventors: Jason Gill, Paul Loadman, Rob Falconer, Laurence Patterson, Jennifer Xavier, Michael Bibby
  • Compounds containing a vascular disrupting agent
    Patent number: 9358303
    Abstract: The present invention relates to compounds, and pharmaceutically acceptable salts thereof, comprising a vascular disrupting agent (VDA) associated and a MMP proteolytic cleavage site. The compounds are useful in the treatment of cancer.
    Type: Grant
    Filed: December 17, 2013
    Date of Patent: June 7, 2016
    Assignee: Incanthera Ltd
    Inventors: Jason Gill, Paul Loadman, Rob Falconer, Laurence Patterson, Jennifer Xavier, Michael Bibby
  • Compounds
    Publication number: 20150196658
    Abstract: The present invention relates to prodrugs of vascular disrupting agents comprising a vascular disrupting agent (VDA) associated with a MMP proteolytic cleavage site and to the use of such prodrugs in the targeted treatment of cancer.
    Type: Application
    Filed: November 25, 2014
    Publication date: July 16, 2015
    Inventors: Robert Andrew Falconer, Jason Gill, Jennifer Xavier, Paul Loadman, Michael Bibby, Laurence Patterson
  • Compounds
    Patent number: 8927486
    Abstract: The present invention relates to prodrugs of vascular disrupting agents comprising a vascular disrupting agent (VDA) associated with a matrix metalloproteinase (MMP) proteolytic cleavage site and to the use of such prodrugs in the targeted treatment of cancer.
    Type: Grant
    Filed: October 20, 2009
    Date of Patent: January 6, 2015
    Assignee: Incanthera Limited
    Inventors: Robert Falconer, Jason Gill, Jennifer Atkinson, Paul Loadman, Michael Bibby, Laurence Patterson
  • Compounds
    Publication number: 20140179592
    Abstract: The present invention relates to compounds, and pharmaceutically acceptable salts thereof, comprising a vascular disrupting agent (VDA) associated and a MMP proteolytic cleavage site. The compounds are useful in the treatment of cancer.
    Type: Application
    Filed: December 17, 2013
    Publication date: June 26, 2014
    Applicant: INCANTHERA LIMITED
    Inventors: Jason Gill, Paul Loadman, Rob Falconer, Lawrence Patterson, Jennifer Atkinson, Michael Bibby
  • COMPOUNDS
    Publication number: 20110275554
    Abstract: The present invention relates to prodrugs of vascular disrupting agents comprising a vascular disrupting agent (VDA) associated with a MMP proteolytic cleavage site and to the use of such prodrugs in the targeted treatment of cancer.
    Type: Application
    Filed: October 20, 2009
    Publication date: November 10, 2011
    Applicant: The University of Bradford
    Inventors: Robert Andrew Falconer, Jason Gill, Jennifer Atkinson, Paul Loadman, Michael Bibby, Laurence Patterson